MARKET

AERI

AERI

Aerie Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

21.59
+1.70
+8.55%
After Hours: 21.59 0 0.00% 16:00 02/21 EST
OPEN
22.40
PREV CLOSE
19.89
HIGH
22.75
LOW
20.06
VOLUME
2.98M
TURNOVER
--
52 WEEK HIGH
50.10
52 WEEK LOW
17.15
MARKET CAP
1.00B
P/E (TTM)
-4.9918
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of AERI and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 13 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average AERI stock price target is 38.08 with a high estimate of 54.00 and a low estimate of 26.00.

EPS

AERI News

More
  • Edited Transcript of AERI earnings conference call or presentation 20-Feb-20 10:00pm GMT
  • Thomson Reuters StreetEvents · 1d ago
  • Here's Why Aerie Pharmaceuticals Jumped as Much as 14.4% Today
  • MotleyFool.com · 1d ago
  • Aerie Pharma up 14% premarket on Q4 revenue beat
  • seekingalpha · 1d ago
  • Aerie's (AERI) Q4 Loss Wider Than Expected, Revenues Beat
  • Zacks · 1d ago

Industry

Biotechnology & Medical Research
+0.37%
Pharmaceuticals & Medical Research
+0.54%

Hot Stocks

Symbol
Price
%Change
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

About AERI

Aerie Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company's product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan). The Company's product candidates are designed to lower intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension. Its Rhopressa is a once-daily eye drop. Rhopressa inhibits Rho kinase (ROCK), and the norepinephrine transporter (NET), which are both biochemical targets for lowering IOP. Its Roclatan is a once-daily, fixed-dose combination of Rhopressa and latanoprost, which is a prescribed drug for the treatment of patients with open-angle glaucoma. The Company is engaged in conducting Phase III clinical trial for Roclatan.
More

Webull offers kinds of Aerie Pharmaceuticals Inc stock information, including NASDAQ:AERI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AERI stock news, and many more online research tools to help you make informed decisions.